Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

BD launches FacsDiscover A8 cell analyzer

July 2025—BD announced the worldwide commercial launch of its FacsDiscover A8 cell analyzer. It features BD SpectralFX technology, which maximizes the number of colors that can be used in flow cytometry; BD CellView image technology, which enables high-speed fluorescent and label-free imaging of single cells; and intuitive software workflows that allow for effective management of large data sets. The analyzer pairs with BD FacsDiscover cell sorters and BD reagents.

FDA clears Sysmex CN-6000 automated blood coag analyzer

July 2025—Sysmex America has received FDA clearance for its CN-6000 automated blood coagulation analyzer. The clearance also covers reagent products for prothrombin time seconds and PT INR (Dade Innovin), activated partial thromboplastin time (Dade Actin FSL), fibrinogen (Dade thrombin reagent), antithrombin (Innovance antithrombin), and D-dimer (Innovance D-dimer). Sysmex has also received Health Canada license for the CN-6000 as well as its CN-3000 automated blood coagulation analyzer.

Empire Genomics, BioDot to launch hematology FISH probe panels

July 2025—Empire Genomics and BioDot have partnered to launch a line of hematology-focused FISH probe panels and controls. The BDot Probe line is preoptimized, ready to use, and validated for performance on the BioDot CellWriter S platform. The initial release of the panels includes targeted solutions for FISH analysis of a range of hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, chronic myelogenous leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, and other common hematologic disorders.

Pillar raises $34.5 million in funding

July 2025—Pillar Biosciences announced it has finalized $34.5 million in funding, which includes a strategic investment from Illumina and structured financing from Soleus Capital, as well as investments from existing investors. The proceeds will be leveraged to advance commercial activities, including infrastructure to support biopharma partnerships, and expand adoption of its distributable clinical testing kits.

Agilent unveils InfinityLab Pro iQ series

July 2025—Agilent Technologies has launched its Agilent InfinityLab Pro iQ series of mass detectors for liquid chromatography. The series includes the InfinityLab Pro iQ and InfinityLab Pro iQ Plus and supports applications such as mass confirmation, impurity profiling, biomolecule characterization, trace contaminant detection, and compound purification. The Pro iQ system, with a mass range of m/z 2–1,600, is optimized for small molecule analysis, while the Pro iQ Plus system is engineered for high-end applications and has a mass range of m/z 2–3,000.

Qiagen plans launch of three sample prep instruments

July 2025—Qiagen plans to launch three sample preparation instruments this year and next to expand its portfolio for automated sample preparation. QIAsymphony Connect, the next generation of the QIAsymphony, is progressing toward a phased launch to selected customers this year. The system, for in vitro diagnostic use, addresses pathogen nucleic acid extraction and other applications and can process up to 96 samples at a time. It features improved automation capabilities for sample tracking and new applications, higher yield for increase in assay sensitivity, and digital connectivity.

Labcorp launches MRD, liquid biopsy solutions

July 2025—Labcorp has expanded its precision oncology portfolio with its Labcorp Plasma Detect, to help assess the risk of disease recurrence in stage three colon cancer patients, and PGDx Elio Plasma Focus Dx, a kitted, pan-solid tumor liquid biopsy test authorized by the FDA to identify patients who may benefit from targeted treatments.

ARUP launches pTau 217 blood test

July 2025—ARUP Laboratories now provides a blood test for phosphorylated tau 217 to assist in identifying whether symptoms of cognitive decline in patients ages 60 years and older are related to Alzheimer’s disease pathology.

BD gets FDA 510(k) clearance for advanced microbiology solution

July 2025—BD announced FDA 510(k) clearance for the BD Phoenix M50 automated microbiology solution and BDXpert system on the BD Synapsys informatics solution, leveraging rapid identification and antimicrobial susceptibility testing algorithms to assist in interpreting complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance. BDXpert is an automated, rule-based system that analyzes ID and AST results from the BD Phoenix M50 system.

Techcyte launches wet mount iodine solution

July 2025—Techcyte announced the launch of its wet mount iodine solution for research use only in the United States. The AI-assisted screening tool is designed to help users locate, count, and preclassify parasites from iodine-stained fecal slides. The solution is part of Techcyte’s Fusion parasitology suite, which includes the company’s trichrome and modified acid fast solutions.

MARKETPLACE

TRENDING